| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11786508 | BIOXCEL | Use of sublingual dexmedetomidine for the treatment of agitation |
Dec, 2037
(13 years from now) | |
| US11839604 | BIOXCEL | Use of sublingual dexmedetomidine for the treatment of agitation |
Dec, 2037
(13 years from now) | |
| US10792246 | BIOXCEL | Film formulations containing dexmedetomidine and methods of producing them |
Jun, 2039
(15 years from now) | |
| US11497711 | BIOXCEL | Film formulations containing dexmedetomidine and methods of producing them |
Jun, 2039
(15 years from now) | |
| US11517524 | BIOXCEL | Film formulations containing dexmedetomidine and methods of producing them |
Jun, 2039
(15 years from now) | |
| US11478422 | BIOXCEL | Film formulations containing dexmedetomidine and methods of producing them |
Jun, 2039
(15 years from now) | |
| US11806334 | BIOXCEL | Non-sedating dexmedetomidine treatment regimens |
Jan, 2043
(18 years from now) | |
Igalmi is owned by Bioxcel.
Igalmi contains Dexmedetomidine Hydrochloride.
Igalmi has a total of 7 drug patents out of which 0 drug patents have expired.
Igalmi was authorised for market use on 05 April, 2022.
Igalmi is available in film;buccal, sublingual dosage forms.
Igalmi can be used as acute treatment of agitation associated with schizophrenia or bipolar i or ii disorder by sublingual administration, acute treatment of agitation associated with schizophrenia or bipolar i or ii disorder by sublingual or buccal administration in patients with severe hepatic impairment, acute treatment of agitation associated with schizophrenia or bipolar i or ii disorder by buccal administration, acute treatment of agitation associated with bipolar i or ii disorder by sublingual or buccal administration, acute treatment of agitation associated with schizophrenia by sublingual or buccal administration.
The generics of Igalmi are possible to be released after 12 January, 2043.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Apr 05, 2025 |
Drugs and Companies using DEXMEDETOMIDINE HYDROCHLORIDE ingredient
Market Authorisation Date: 05 April, 2022
Treatment: Acute treatment of agitation associated with schizophrenia by sublingual or buccal administration; Acute treatment of agitation associated with bipolar i or ii disorder by sublingual or buccal adminis...
Dosage: FILM;BUCCAL, SUBLINGUAL
IGALMI family patents
